To order this 450+ page report, please visit this link Key InclusionsAn overview of the overall landscape of antibody discovery service providers along with the information on a number of parameters, such as year of establishment, company size, location of headquarters, type of service offered (antigen designing, hit generation, lead selection, and lead optimization and lead characterization), type of antibody discovery method (hybridoma based, library based, single cell based, transgenic animal based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others), type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others) and purpose of antibody discovery (therapeutic and diagnostic).An insightful competitiveness analysis of antibody discovery service providers, based on supplier strength (based on a company's employee count and years of experience) and service portfolio specifications, such as number of antibody discovery services offered, number of antibody discovery methods adopted, and number of subject specific agreements signed.Elaborate profiles of antibody discovery service providers.
Each company profile features a brief overview of the company, its financial information (if available), antibody discovery service portfolios and an informed future outlook.A detailed review of the overall landscape of antibody discovery platforms, along with the information on the technology developers such as year of establishment, company size, location of headquarters and type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others).
In addition, the chapter highlights an in-depth analysis of antibody discovery platforms based on type of antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others) and availability of intellectual property.A detailed competitiveness analysis of antibody discovery platforms, taking into consideration the supplier power (based on the year of establishment of developer) and key technology specifications, such as type of antibody discovered, compatibility of antibodies in human (fully human or not), availability of patent protection, number of deals signed for a particular platform between 2015 and 2020.Elaborate profiles of antibody discovery platform providers.
Each company profile features a brief overview of the company, its financial information (if available), details on antibody discovery technology / platform(s) offered and an informed future outlook.An assessment of antibody discovery service and platform providers' capability in different regions, based on a number of relevant parameters.
For platform providers, these parameters include number of technologies offered, number of antibody discovery methods employed, and type of antibody discovered.
On the other hand, the service providers have been evaluated based on the type(s) of service offered.An analysis of the partnerships that have been established in this domain since 2015, covering R collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, clinical trial agreements, and other relevant deals.An analysis of the investments made in this domain, during the period between 2016 and 2020 (till April), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, in companies that are engaged in the field of antibody drug discovery.Detailed profiles on the top five therapeutic antibody products, which have generated the highest revenues.